603939 益丰药房
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入11,762,4019.86%22,588,22719,886,39615,326,30513,144,502
减:营业总成本10,676,8939.81%20,616,59718,008,27514,045,64112,062,111
    其中:营业成本7,051,6129.76%13,957,59912,025,5649,142,8188,152,071
               财务费用73,08485.83%86,185104,812114,870141,522
               资产减值损失(38,798)12.10%(72,634)(56,019)(40,746)(31,404)
公允价值变动收益------------
投资收益49,44765.79%42,3726,86934,36829,420
    其中:对联营企业和合营企业的投资收益(1)-42.22%317(11)--2,168
营业利润1,133,9679.80%2,054,7851,885,5331,338,8671,133,484
利润总额1,131,4969.67%2,037,5941,877,4871,337,9061,127,365
减:所得税费用271,42616.57%456,663454,061347,157287,923
净利润860,0717.66%1,580,9311,423,426990,749839,443
减:非控股权益62,352-33.46%168,946161,585102,86495,920
股东净利润797,71813.13%1,411,9851,261,841887,884743,523

市场价值指针
每股收益 (元) *0.66013.79%1.4001.2601.2501.080
每股派息 (元) *0.250--0.5000.4000.3000.300
每股净资产 (元) *8.238-9.10%9.70211.85510.4099.883
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容